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Abstract Only one-third of elderly ([60 years) AML and
MDS-RAEB2 patients may receive intensive chemotherapy
treatment alternatives that are limited in this patient group
due to the potential of severe toxicity. Previous studies have
shown that azacitidine and low dose cytarabine treatments
may be a beneficial treatment option for these patients. In
this study, we aimed to good results with low toxicity in
elderly patients. We retrospectively analyzed the AML and
MDS-RAEB2 patients who received azacitidine mono-
therapy and azacitidine and LDL-ara-c combination therapy
for a comparison of their response to therapy, survival rates,
and toxicity rates and for determining the factors that could
affect their overall survival. A total of 27 patients who were
diagnosed with de novo AML and MDS-RAEB2 and who
received at least four cycles of chemotherapy were included
in the study, and the data were evaluated retrospectively.
When monotherapy and combination therapy groups were
compared, the pretreatment bone marrow blast count was
observed to be greater in the combination therapy group. A
statistically significant difference was not detected between
the groups regarding the response to therapy ratios
(p = 0.161) (42.9 and 57.1 %, respectively). No difference
was detected between the groups regarding therapy-related
toxicity. Infections were the most common complication.
Progression-free survival was 30.3 % for the azacitidine
monotherapy group and 66.7 % for the combination (aza-
citidine ? LD-ara-c) group. The factors influencing the
overall survival rate were determined based on the response
to the first-line therapies, more than a grade 2 infection,
fever, and relapse in a multi-variance analysis. The combi-
nation therapy may be a well-tolerated treatment option for
the elderly, vulnerable AML patients whose blast count is
high in response to therapy rates, overall survival rates, and
toxicities are not different, although the pre-treatment bone
marrow blast count was greater in the combination therapy
groups compared with the monotherapy group.
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Introduction
Acute myeloid leukemia (AML) is an agressive disease
with a poor prognosis. Only 1/3 of the elderly ([60 years)
AML patients may receive intensive chemotherapy proto-
cols [1]. The patients who cannot receive intensive che-
motherapy are given either only a effective supportive
therapy or protocols that contain low doses of cytosine
arabinoside (LD-ara-c) [1], azacitidine [2], clofarabine [3],
and gemtuzumab ozogamicin [4]. DNA hypermethylation
is the most common permanent pathogenetic process
observed in MDS and AML patients. DNA methylation
may be effectively achieved by the inhibition of DNA
methyltransferase [5]. Phase III trials conducted with aza-
citidine, a DNA methyltransferase inhibitor, showed that
azacitidine improved cytopenias and prolonged overall
survival compared with beneficial supportive therapies or
conventional regimens in MDS and AML patients [2, 6, 7].
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Cytosine arabinoside is the nucleoside analogue of de-
oxycitidine. LD-ara-c is widely used in the elderly AML
patients [5]. The response to cytarabine therapy was shown to
be better in the elderly AML patients in the study which was
comparing low dose cytarabine and hydroxyurea [1]. In a
study conducted on relapsed and refractory high riskMDSand
AML patients, the combination of azacitidine and varying
doses of LD-ara-c was shown to have a limited effect and was
recommended as an alternative therapy [5]. A similar study
was conducted onMDSRAEBpatients, and it was shown that
the response rates increased; however, this combination did
not have an effect on leukemic transformation [8].
Based on these studies, we aimed to get good response
with low toxicity. We administered to our patients azaciti-
dine plus LD-ara-c combination and thereafter we compared
with monotherapy azacitidine which taken patients who
were diagnosed as MDS-RAEB2 and AML. We retrospec-
tively analyzed the monotherapy and combination therapy
for a comparison of their efficacy and the toxicity rates.
Patients and Study Method
Patients and Data Collection
A total of 32 newly diagnosed AML and MDS-RAEB2
patients who were followed up with in the Hematology
Department of Bas¸kent University between December of
2010 and January of 2014 were screened retrospectively. Of
these patients, 5 were excluded because they died following
one cycle of chemotherapy. Twenty-seven newly diagnosed
AML and RAEB2 patients were included in the study.
Inclusion criteria included being above 60 years of age,
being a newly diagnosed and no history of prior hematho-
logical disease and received chemotherapy for AML or
MDS-RAEB2 (according to the World Health Organization
(WHO)-2008 classification [8], at least four course of aza-
citidine containing chemotherapy regimen, an agreement to
received chemotherapy patients didn’t accept to receive
standart chemotherapy protocols, patients who have been
more than 2 comorbidities with high risk for standart che-
motherapy protocol. Exclusion criteria are; AML patients
could received the standart chemotherapy did not partici-
pate the study, patients received less than four cycle aza-
citidine containing regimen.
Treatment Method
Azacitidine monotherapy was given to the patients which
were diagnosed as MDS-RAEB-2 and have been several
comorbidities. LD-ara-c plus azacitidine combination therapy
was applied to the patient whowere diagnosedAMLwith less
than 2 comorbidities and patients can be tolerated to the
combination therapy. Azacitidine monotherapy was applied
in the dose of 75 mg/m2 daily via a subcutaneous route for
7 days in every 28 days. Cytarabine and azacitidine was
administered 7 days at 20 mg/m2 daily for 10 days sucuta-
neously and 75 mg/m2 daily for 7 days, respectively. Both of
the monotherapy and combination therapy was applied every
28 days for at least four cycles. Non-responders were
administered decitabine at 20 mg/m2 daily for 5 days or cyt-
arabine at 100 mg/m2 daily for 5 days, and idarubicine at
12 mg/m2 daily was used as a second line of therapy. The
patients who responded to therapy continued their prior che-
motherapy protocol, which provided remission until the time
of relapse.All patients received posaconazole at 200 mg tid as
an antifungal prophylaxis and PO valacyclovir at 500 mg bid
as an antiviral prophylaxis during the entire therapy process.
Assessment of the Response to Therapy
A whole blood count was performed before treatment, and a
bone marrow biopsy, a bone marrow aspiration, and a flow
cytometric analysis were conducted after the completion of
4 cycles of chemotherapy for each patient. The response to
therapy was evaluated as a morphologic complete response
(CR), a compete response with an incomplete blood count
recovery (CRi), a partial response (PR), and irresponsive-
ness. The patients in both groups were compared regarding
the overall survival, the response rates, the blast count in the
bone marrow before and after treatment, the frequency of
treatment-related complications, and the need for a blood
transfusion during therapy. Progression free survival was
defined as the beginning time of the diagnosis and at the
time of relapsing and the beginning of the second line
chemotherapy regimen. Overall survival was defined as
beginning at the time of diagnosis and ending at the time of
death. The surviving patients were censored.
Statistical Method
The SPSS 21.0 statistical package program was used for the
statistical analysis. The descriptive statistics were presented
as the number and the percent for categorical variables and
presented as the mean, the standard deviation, the median,
the minimum, and the maximum for numerical variables.
For a comparison of the multiple independent groups, a qui-
square test was used for paired and multiple comparisons
when the qui-square condition was provided for the cate-
gorical variables, the Monte Carlo simulation was used for
multiple comparisons, and the Fisher’s exact test was used
for paired groups. The survival analysis was conducted
using the Kaplan–Meier method, and log-rank statistics
were used for comparisons. The cox regression analysis was
used with the Stepwise method for the multivariance ana-
lysis of the risk factors that were found to be significant in
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the univarite Kaplan–Meier analysis (Fig. 1). The results
were evaluated in a 95 % confidence interval, and a p level
of\0.05 was accepted as statistically significant.
Results
Patient Characteristics
The mean age of the 27 patients was determined to be
71.30 ± 6.79 (mean ± SD). Of the patients, 12 (44.4 %)
were female, and 15 (55.6 %) were male. Nineteen
(70.37 %) were being followed up with a diagnosis of
AML, and 8 (29.63 %) were being followed up with a
diagnosis of MDA-RAEB2. The patients were evaluated
separately as the azacitidine monotherapy group (51.9 %;
n = 14) and the azacitidine ? LD-ara-c combination
therapy group (48,1 %; n = 13) and compared statistically.
The patient characteristics of both groups are summarized
in Table 1. While the metaphasis could not be provided in
5 (18.5 %) out of 13 (48 %) patients in which a cytogenetic
evaluation was performed, a complex karyotype was
detected in 4 (14.8 %), and a normal karyotype was found
in 4 (14.8 %). Because of molecular studies couldn’t
studied in our center, we couldn’t known the patients
molecular status. A significant difference was not detected
between the groups with regard to gender, survival, number
of cycles, antibiotic-requiring infection, skin reaction.
Number of patients who have more than 2 comorbidities
were 5 in monotherapy group and 3 in combination group
and this comorbidity numbers were not statistically dif-
ferent. The pre treatment blast percent of the patients in the
azacitidine monotherapy group (31.430 ± 22.432) was
lower than that of the azacitidine ? LD-ara-c combination
therapy group (51.310 ± 22.054) (p = 0.014). The platelet
requirement was low in the azacitidine monotherapy group
which was statistically significant in first 2 cycles and the
second 2 cycles (2.360 ± 4.378 Units, 7.920 ± 6.788
Units, p = 0.004, 2.500 ± 8.528 Units, 7.080 ± 9.561
Units, p = 0.017 respectively).
The erythrocyte requriment during first 2 cycles and the
second 2 cycles was higher in the patients who did not
respond to first line therapy compared with that of the
patients who responded to therapy (8.880 ± 4.443 Units,
5.580 ± 4.033 Units, p = 0.033,9.200 ± 6.026 Units,
0.920 ± 1.881 Units, p = 0.000, respectively).
Response to the Treatment
The responses to first line therapy are summarized in
Table 2. The overall response rate was found to be 42.9
and 57.1 % for the azacitidine monotherapy group and the
combination therapy group, respectively, and a statistically
significant difference was not detected between these two
rates (p = 0.161). Five and four patients in the mono-
therapy and the combination therapy groups were received
second line chemotherapy regiment. In monotherapy
group, four patients were received decitabine an done
patient was received 2 ? 5 CT protocole because of acute
leucemic transformation from MDS-RAEB2 with high
blast count. In combination group, three patients were
received 2 ? 5 Ct protocole and one patient was received
decitabine. One patient underwent a haploidentical bone
marrow transplantation following the azacitidine treatment.
Fig. 1 Kaplan–Meier overall survival and progression free survival
curves of the patients who used the monotherapy azacytidine and
those who used the azacytidine ? cytarabine combination therapy as
the initial therapy
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Treatment-Related Toxicity
The distribution of the toxicities based on the azacitidine
monotherapy and the azacitidine-LD-ara-c combination
treatment is summarized in Table 3. A statistically signif-
icant difference was not detected between the groups
regarding the presence of antibiotic-requiring infection,
skin reaction, need for additional antiemetic drugs, fever,
duration of hospital stay due to infection, and the degree of
neutopenia, leukopenia, thrombocytopenia, and anemia.
Impaired liver function tests were not observed in the
patients.
The median duration of the follow-up was determined
to be 9.5 ± 9.628 (4–41 months) for all patients. The
overall survival rate of the patients who received azacit-
idine monotherapy was 77.4 % for 1 year and 29.0 % for
2, 3, and 4 years, and it was 48.6 % for 1 year and
36.5 % for 2, 3, and 4 years in patients who received
combination therapy. A statistically significant difference
was not detected in the overall survival rates of the two
groups (p = 0.321). The mean and the median of the
overall survival rates and the follow-up are summarized in
Table 4.
The progression-free survival rate was 30.3 % for 1 year
in the monotherapy group, and 66.7 % for 1, 2, and 3 years
in the combination group. A statistically significant dif-
ference was not detected in the survival rates of the groups
(p = 0.481). The mean and the median of the overall
survival rates and the follow-up duration of the treatment
groups are summarized in Table 5.
The factors influencing the overall survival rate were
evaluated. Overall survival was significantly longer in the
patients who responded to first line therapy compared with
the non-responders, who did not develop an infection
Table 1 Characteristics of patients who used azacytidine ? LD-ara-c combination and who used azacytidine monotherapy as the initial therapy
Parameters Azacytidine ? LD-ara-c
combination therapy (N = 14)
Azacytidine therapy (N = 13) P
Age (year) 69.00 ± 6.014 73.430 ± 6.98 0.072
WBC before CT (ll) 10213,850 ± 18429,886 15027,640 ± 23125,509 0.264
WBC after CT (ll) 8892,380 ± 10433,890 4118,710 ± 5099,554 0.159
Hemoglobin before CT (g/dl) 8.206 ± 1.677 8.069 ± 1332 0.942
Hemoglobin after CT (g/dl) 10.185 ± 2.742 9.949 ± 2.345 0.846
Platelet before CT (ll) 54353,850 ± 40665,416 68558,570 ± 57031,948 0.771
Platelet after CT (ll) 92092,310 ± 85631,366 140282,140 ± 137635,654 0.593
ANC before CT (ll) 5578,690 ± 16146,351 3321,430 ± 7492,055 0.771
ANC after CT (ll) 1365,380 ± 1530,978 1630,500 ± 1444,255 0.422
Bone marrow blast before CT (%) 51.310 ± 22.054 31.430 ± 22.43 0.014*
Bone marrow blast after CT (%) 21.150 ± 24.72 7.570 ± 8.591 0.124
Number of CT (%) 4.640 ± 1.336 4.230 ± 0.832 0.326
E.S. transfusion (unit) during 1 ? 2 cycles 8,620 ± 4,718 6.210 ± 4,098 0.213
E.S. transfusion (unit) during 3 ? 4 cycles 6,690 ± 5,202 4.430 ± 7,046 0.154
P.S. transfusion (unit) during 1 ? 2 cycles 7,920 ± 6,788 2,360 ± 4,378 0.004*
P.S. transfusion (unit) during 3 ? 4 cycles 7,920 ± 9,561 2,500 ± 8,528 0.017*
Remission duration (month) 7,080 ± 6,959 6,690 ± 5,202 0.622
Overall survival time (month) 10,770 ± 9.619 12,790 ± 9,529 0.407
WBC white blood cells, ANC absolute neutrophil count CT chemotherapy, E.S erythrocyte suspension, P.S apheresis platelet suspension
Table 2 Responses of the
patients who used
azacytidine ? LD-ara-c
combination therapy and who
used monotherapy azacytidine
as the initial therapy
CR complete remission, CRi
complete remission with
incomplete blood count
recovery
Azacytidine n (%) Azacytidine ? LD-ara-c
combination therapy n (%)
p
Response to therapy 0.161
Morphologic CR 5 (35,7) 4 (30,8)
Cri 3 (4, 21) –
Partial remission – 3 (23,1)
Treatment failure – 2 (15,4)
Stable disease 6 (42,9) 4 (30,8)
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compared with the patients whose grade of infection was
greater than two and whose bone marrow blast ratio
returned to normal (p = 0.007, p = 0.008, p = 0.000,
respectively). Overall survival was significantly shorter in
the patients who had fever compared with the patients
without fever and who relapsed after 4 cycles of chemo-
therapy compared with the patients who did not relapse
(p = 0.037, p = 0.001). The influence of other factors on
the overall survival rate was not statistically significant.
The data that were found to be significant in a univarite
Kaplan–Meier analysis were analyzed using the cox
regression analysis. The bone marrow blast count after
chemotherapy was observed to be significant. The patients
with a blast count of more than[20 % shortened overall
survival 37.051 fold compare with the patients whose blast
count was\5 %.
Table 3 Toxicities of the
patients who used
azacytidine ? cytarabine
combination and who used
azacytidine monotherapy
Azacytidine
monotherapy
(n, %)
Azacytidine ? LD-ara-c
combination therapy (n, %)
p
Antibiotic-requiring infection
No 7 (50,0) 4 (30,8) 0.559
Yes 7 (50,0) 9 (69,2)
Skin reaction
No 5 (35,7) 2 (15,4) 0.487
Yes 9 (64,3) 11 (84,6)
Nausea
Grade 1 10 (71,4) 5 (38,5) 0.075
Grade 2 4 (28,6) 7 (53,8)
Grade 3 0 (0,0) 1 (7,7)
Infection
No 6 (42,9) 2 (15,4) 0.393
Grade 1 – 2 (15,4)
Grade 2 4 (28,6) 3 (23,1)
Grade 3 2 (14,3) 6 (46,2)
Grade 4 2 (14,3) 0 (0,0)
Diarrhea
No 11 (78,6) 10 (76,9) 0.841
Grade 1 3 (21,4) 2 (15,4)
Grade 2 0 (0,0) 1 (7,7)
Need for additional antiemetic drugs
No 5 (35,7) 5 (38,5) 0.885
Yes 9 (64,3) 8 (61,5)
Treatment-related fever
No 8 (57,1) 5 (38,5) 0.341
Grade 1 6 (42,9) 8 (61,5)
Leukopenia
Grade 1 4 (28,6) 2 (15,4) 0.309
Grade 2 5 (35,7) 4 (30,8)
Grade 3 5 (35,7) 7 (53,8)
Thrombocytopenia
Grade 1 6 (42,9) 3 (23,1) 0.073
Grade 2 4 (28,6) 1 (7,7)
Grade 3 4 (28,6) 9 (69,2)
Anemia
Grade 1 3 (21,4) 2 (15,4) 0.130
Grade 2 5 (35,7) 1 (7,7)
Grade 3 6 (42,9) 10 (76,9)
Duration of hospital stay (Median ± SD, day) 10.140 ± 10.41 7.850 ± 11.77 0.341
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Discussion
In this study, we aimed to compare azacitidine mono-
therapy and azacitidine ? LD-ara-c combination therapies
in newly diagnosed AML and RAEB2 patents who had a
high blast count ([30 %) and who were not previously
treated. To the best of our knowledge, this is the first study
of this kind in the literature. The median duration of fol-
low-up was determined to be 9.5 ± 9.628 (4–41 months).
Median overall survival was not a statistically significant
difference in both CT group (p = 0.407). The estimated
median overall survival was higher in the monotherapy
group but there was no statistically difference in both
group. This situation can attributed to the small number of
patients but on the other hand the patients who were in the
combination group have more number of comorbidities and
more blast counts. Besides the estimated progression free
survival was longer in the combination therapy group
despite the higher blast counts in the bone marrow. It may
be related to the higher efficacy this treatment schedule but
the larger studies must be planned. In a retrospective study
conducted by Radujkovic et al., azacitidine and LD-ara-c
treatments were compared, and response rates were deter-
mined to be 14 and 7 %, respectively [1]. In a multi-center
study conducted with 155 AML patients, while the overall
response rate was determined to be 52.3 %, the median
overall survival as 9.8 months with azacitidine therapy,
similarly to ours, these rates were reported as 33 % and
9.4 months in another multi-center study including 149
patients [12, 13]. Pleyer et al. reported in a large pro-
spective trial that azacitidine can be safely and effectively
used in elderly patients. In this study, 302 patients were
evaluated. The overall response rate was 48 %, and the
median overall survival was 9.6 months [14].
Radujkovic et al. reported in their study, while a sta-
tistically significant difference was not detected between
the response to therapy rates and the toxicities, the one-
year survival rate expectation was determined to be 15 and
13 % in comparing azacitidine and LD-ara-c treatments
[11], respectively. Varying doses of cytarabine and aza-
citidine combination were used in combinations in a study
conducted with an azacitidine and an LD-ara-c combina-
tion [5]. The overall response rate was reported to be 50 %,
and the CR rate was reported to be 33.3 % following 2
cycles of therapy [5]. In another type of combination study
was published in 2012. In this study, azacitidine and LD-
ara-c combination therapy was administered in the same
doses as in our study. The overall response rate was
reported to be 50 %, and the median overall survival rate
was reported to be 487 days [8]. Although the overall
response rates are similar in this study and in our study, this
situation may associate with a longer median survival with
all patients being diagnosed as MDS [8]. In addition, var-
ious studies are available that used lenalidomide [15],
panobinostate [16], bortezomib [17], and erlitinib [18] in
combination with azacitidine in order to achieve better
response rates in the elderly.
In our study, the factors influencing overall survival
were found to be the response to first line therapy, the
presence of grade 2 and above infection during treatment,
and relapsing after treatment or being refractory to treat-
ment in the multivariance analysis. According to previous
studies, the cytogenetic factors determining the prognosis
in AML patients were determined to be complete karyo-
type, MK positivity, 5.chromosome anomalies (-5, 5q-),
7.chromosome anomalies (-7, 7q-), 11q23abnl anomaly,
inversion [3] and molecular factors such as an elevated
expression of EVI1 (ectopic virus integration-1), an
Table 4 Overall survival follow up durations of the patients in azacytidine monotherapy and azacytidine ? LD-ara-c combination therapy
group
Mean Median
Estimation SE 95 % CI Estimation SE 95 % CI
Azacytidine 21.59 5.23 11.038 32.774 20.000 3.8 15.425 24.575
Azacytidine ? LD-ara-c 19.288 4.919 9.647 28.929 9.000 4.740 0.000 18.291
Overall survival of whole group of the patients 19.985 3084.003 12.140 27.830 17.000 4.851 7.492 26.508
p = 0.264
Table 5 Progression-free
survival follow up durations of
treatment groups
p = 0.481
Mean
Estimation SE 95 % CI
Azacytidine 6.545 0.755 5.065 8.025
Azacytidine ? LD-ara-c 17.111 3.253 10.736 23.486
Progression-free survival of whole group of the patients 13.417 2.508 8.501 18.332
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absence of NPM1 mutation along with normal cytogenetics,
and the presence of FLT3-ITD mutation [19]. We detected a
complex karyotype in four (14.8 %) of our patients, but a
statistical analysis was not conducted due to a small number
of patients. Chen et al. reported that the pretreatment factors
that influence prognosis were found to be a good perfor-
mance score (Eastern Cooperative Oncology Group PS 0-1),
LDH level (higher than 2 fold of normal), hyperleukocytosis
(WBC[ 100 000/ll), significant thrombocytopenia (\ 20
000/ll) in 205 AML patients [20]. In a study conducted on
149 AML patients having a poor cytogenetic structure,
WBC[ 15 000/ll, the ECOG performance score C2, and
the response to therapy were determined to be the factors
influencing overall survival [13].
When the side effects were analyzed in both treatment
groups, a statistically significant difference was not
detected between treatment-related neutropenia, thrombo-
cytopenia, anemia, the amount of blood transfusion, grade
of infection, diarrhea, skin reaction, hospitalization-
requiring infection, and duration of hospital stay, and this is
consistent with the literature [11, 21, 22].
The severity of infection ([grade 2 according to CTC),
which was one of the most common problems in our patient
group, was determined to be a factor influencing survival.
Conclusions
In conclusion, treatment responses, toxicities, and the
factors influencing the survival of the azacitidine and the
azacitidine ? LD-ara-c combination groups were found to
be consistent with the literature despite the small number of
patients in our study. The response rates to therapy, overall
survival, progression free survival and toxicities were not
significantly different, although the pre-treatment bone
marrow blast count was greater in the combination therapy
group compared with the monotherapy group. We propose
that this combination therapy may be a well-tolerated
treatment option for the elderly, vulnerable AML patients
whose blast count is high. Performing prospective studies
with larger number of patients may be beneficial for
determination of the results of the combination therapy in
elderly patients.
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